QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, October 8, 2003, 23(27):9107-9115

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (31) Citing Articles via Google Scholar Google Scholar Articles by Iravani, M. M. Articles by Jenner, P. Search for Related Content PubMed PubMed Citation Articles by Iravani, M. M. Articles by Jenner, P.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

Mahmoud M. Iravani, Michael J. Jackson, Mikko Kuoppamäki, Lance A. Smith, and Peter Jenner

Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, United Kingdom

Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of L-3,4-dihydroxyphenylalanine (L-DOPA) while suppressing dyskinesia in a single patient with Parkinson's disease (PD). The clinical basis of this effect of MDMA is unknown but may relate to its actions on either dopaminergic or serotoninergic systems in brain.

In normal, drug-naive common marmosets, MDMA administration suppressed motor activity and exploratory behavior. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated, L-DOPA-primed common marmosets, MDMA transiently relieved motor disability but over a period of 60 min worsened motor symptoms. When given in conjunction with L-DOPA, however, MDMA markedly decreased dyskinesia by reducing chorea and to a lesser extent dystonia and decreased locomotor activity to the level observed in normal animals. MDMA similarly alleviated dyskinesia induced by the selective dopamine D2/3 agonist pramipexole. The actions of MDMA appeared to be mediated through 5-HT mechanisms because its effects were fully blocked by the selective serotonin reuptake inhibitor fluvoxamine. Furthermore, the effect of MDMA on L-DOPA-induced motor activity and dyskinesia was partially inhibited by 5-HT1a/b antagonists. The ability of MDMA to inhibit dyskinesia results from its broad spectrum of action on 5-HT systems. Serotoninergic receptors appear to play an important modulatory role in L-DOPA-induced dyskinesia, and this study may provide a framework for the use of serotoninergic agents in the treatment of L-DOPA-induced dyskinesia.

Key words: common marmosets; MPTP; dyskinesia; L-DOPA; 3,4-methylenedioxymethamphetamine; MDMA; ecstasy; Parkinson's disease; dopamine; serotonin

---

Received May 14, 2003; revised August 20, 2003; accepted August 20, 2003.

This article has been cited by other articles:

				A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, December 1, 2008; 131(12): 3380 - 3394. [Abstract] [Full Text] [PDF]

				S. J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.-J. Chang, M. Guttman, and Y. Furukawa Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain, January 1, 2008; 131(1): 120 - 131. [Abstract] [Full Text] [PDF]

				S. Mounayar, S. Boulet, D. Tande, C. Jan, M. Pessiglione, E. C. Hirsch, J. Feger, M. Savasta, C. Francois, and L. Tremblay A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery Brain, November 1, 2007; 130(11): 2898 - 2914. [Abstract] [Full Text] [PDF]

				M. M. Iravani, K. Tayarani-Binazir, W. B. Chu, M. J. Jackson, and P. Jenner In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1225 - 1234. [Abstract] [Full Text] [PDF]

				T. D. Sotnikova, M. G. Caron, and R. R. Gainetdinov DDD mice, a novel acute mouse model of Parkinson's disease. Neurology, October 10, 2006; 67(7 Suppl 2): S12 - S17. [Abstract] [Full Text]

				M. P. Hill, P. Ravenscroft, E. Bezard, A. R. Crossman, J. M. Brotchie, A. Michel, R. Grimee, and H. Klitgaard Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 386 - 394. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help